CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
- Friday, December 13, 2019, 7:00
- Finance
- Add a comment
INDIANAPOLIS, Dec. 13, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending a new indication and associated label update for CYRAMZA®…
About the Author
adminasapcorp has written 42188 stories on this site.